Allogeneic T cells genetically modified to express a truncated form of human ΔLNGFR and the HSV-TK

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAllogeneic T cells genetically modified to express a truncated form of human ΔLNGFR and the HSV-TK
Drug Alias NameHerpes simplex virus thymidine kinase (HSV-Tk) donor lymphocytesNalotimagene carmaleucelTK cell therapy-MolMedZalmoxisHSV-Tk +[6] 
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector
Mechanisms of ActiondGTP(deoxyguanosine triphosphate) antagonistsGene transference
TargetsdGTP(deoxyguanosine triphosphate)
Therapy Area/IndicationsGraft vs Host DiseaseMyelodysplastic SyndromesLymphoma, Non-Hodgkin +[6] 
Global Approved IndicationsGraft vs Host Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2016/08/18
Country/TerritoryUnited StatesEU
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesMolmed Spa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteMolmed Spa
Active IndicationsN/A
Inactive IndicationsGraft vs Host DiseaseMyelodysplastic SyndromesLymphoma, Non-Hodgkin +[6] 

Other Information

ATC CodeL01
Related LinksWikipedia